Summary & Overview
HCPCS Q5125: Filgrastim-ayow (Releuko) Injection, 1 microgram
HCPCS Level II code Q5125 denotes the injection of filgrastim-ayow (Releuko), a biosimilar granulocyte colony-stimulating factor, billed per 1 microgram. This code captures the delivery of a biologic supportive-care agent commonly used in oncology to shorten chemotherapy-induced neutropenia and reduce infection risk. Nationally, reporting of biosimilar G-CSF agents like filgrastim-ayow matters for utilization tracking, payer coverage decisions, and biosimilar adoption metrics.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what Q5125 represents clinically and operationally, where the service is typically provided, and which commercial and government payers are relevant to coverage and claims processing. The publication summarizes benchmarks and policy considerations relevant to biosimilar G-CSF use, highlights coding and billing context for outpatient injection services, and outlines areas where data was not available in the input. Data not available in the input includes associated taxonomies, specific ICD-10 diagnosis mappings, and related billing codes.
Billing Code Overview
HCPCS Level II code Q5125 represents an injection of filgrastim-ayow (Releuko), a biosimilar to filgrastim, billed per 1 microgram unit. This code is used to report administration of the biosimilar granulocyte colony-stimulating factor formulation indicated to reduce the duration of neutropenia and the incidence of infection in patients receiving myelosuppressive chemotherapy.
Service Type: Injection / Pharmacologic Support (biosimilar G-CSF)
Typical Site of Service: Outpatient infusion/injection clinic, oncology clinic, physician office, or hospital outpatient department
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving Q5125 is an adult or pediatric oncology patient with chemotherapy-induced neutropenia or at high risk for neutropenic complications following cytotoxic chemotherapy. The clinical workflow begins with the oncology or hematology team ordering a granulocyte colony-stimulating factor (G-CSF) biosimilar — filgrastim-ayow (releuko) — dosed in micrograms based on body weight. The patient presents to an outpatient oncology infusion center, hospital outpatient department, or physician office for administration. Prior to injection, nursing verifies recent complete blood count (CBC) results, weight-based dose calculation, medication reconciliation, and allergy history. The product is prepared under aseptic technique, labeled with lot number and expiration, and administered subcutaneously, typically in the abdomen or thigh. Post-injection monitoring is brief; the patient is observed for immediate adverse events such as injection-site reaction, bone pain, or rare hypersensitivity. Documentation includes the biosimilar product name filgrastim-ayow, NDC or lot number, dose in micrograms, route (subcutaneous), site of administration, and any applicable modifier to indicate circumstances (for example, JW for discarded drug when partial vial contents are wasted). Billing uses Q5125 per microgram with supporting clinical documentation and the appropriate ICD-10 diagnosis indicating neutropenia or chemotherapy regimen intent to reduce febrile neutropenia risk. Typical sites of service: outpatient infusion center, hospital outpatient department, physician office, and occasionally home health when administered by qualified nursing staff.